8-KFiled May 14, 8:00 PM ET

Citius Pharmaceuticals Reports Q2 Fiscal 2026 Results

$CTXR · Citius Pharmaceuticals, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

Citius Pharmaceuticals Reports Q2 Fiscal 2026 Results

What Happened

  • On May 15, 2026, Citius Pharmaceuticals, Inc. (CTXR) announced its results of operations for the second quarter of fiscal 2026 via a press release. The company furnished that press release as Exhibit 99.1 to its Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

  • Filing date: May 15, 2026; Item reported: 2.02 (Results of Operations and Financial Condition).
  • Press release announcing Q2 FY2026 results is furnished as Exhibit 99.1 and incorporated by reference.
  • The filing includes an iXBRL interactive data cover file (Exhibit 104).
  • The 8-K does not disclose additional items such as executive changes or transaction notices (no Item 5.02/1.01 entries in this filing).

Why It Matters

  • This 8-K provides the company’s latest quarterly operating results and financial condition information that investors use to update earnings models, assess cash runway, and re-evaluate valuation and risk.
  • Investors should read the Exhibit 99.1 press release for the specific revenue, profit/loss, cash balance, and any management commentary or guidance; the Form 8-K itself furnishes the release but does not expand beyond incorporating it by reference.